Trophos to file olesoxime after positive data in orphan indication
This article was originally published in Scrip
French pharma Trophos has reported positive top-line data from its pivotal Phase II/III study of olesoxime in spinal muscular atrophy (SMA), a product the company has resolutely backed despite past setbacks.
You may also be interested in...
Promising top-line Phase III data have prompted Biogen to exercise an option to develop and commercialize Ionis's novel antisense treatment nusinersen for infantile-onset spinal muscular atrophy; filings are due shortly.
China's WuXi PharmaTech, an R&D technology company serving the pharmaceutical, biotechnology and medical device industries, has announced construction of a new manufacturing facility in Philadelphia, US designed for cell therapy products, including chimeric antigen receptor T-cell (CAR-T) therapies. More manufacturing power is crucial to the success of this burgeoning, high-potential field.
Takeda has managed to persuade NICE, the health technology appraisal institute for England and Wales, to recommend its ulcerative colitis drug Entyvio (vedolizumab) without the restrictions the institute had previously stipulated – as long as the company offers a discount via a patient access scheme.